NEW YORK (GenomeWeb News) — Promega and China’s Guangzhou Institute of Biomedicine and Health plan to co-develop drug-screening assays, the company said today. 
 
Under the agreement, GIBH researchers will use Promega’s drug-screening assays to develop tests for Cytochrome P450, Kinase, and GPCR profiling.
 
Promega said GIBH, which is part of the Chinese Academy of Sciences, will use the assays for their own research and will offer them through contracts to other companies.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.